Updates in Alzheimer’s disease:from basic research to diagnosis and therapies  

作　　者：Enjie Liu Yao Zhang Jian-Zhi Wang 

机构地区：[1]Department of Pathology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China [2]Department of Endocrine,Liyuan Hospital,Key Laboratory of Ministry of Education for Neurological Disorders,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China [3]Department of Pathophysiology,Key Laboratory of Ministry of Education for Neurological Disorders,School of Basic Medicine,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [4]Co-Innovation Center of Neuroregeneration,Nantong University,Nantong 226000,China

出　　处：《Translational Neurodegeneration》2024年第1期409-456,共48页转化神经变性病(英文)

基　　金：supported in part by the Natural Science Foundation of China(82001134,1949205,31730035,81721005);the Guangdong Provincial Key S&T Program(018B030336001);the Natural Science Foundation of Henan(242300421081).

摘　　要：Alzheimer’s disease(AD)is the most common neurodegenerative disorder,characterized pathologically by extracellular deposition ofβ-amyloid(Aβ)into senile plaques and intracellular accumulation of hyperphosphorylated tau(pTau)as neurofibrillary tangles.Clinically,AD patients show memory deterioration with varying cognitive dysfunctions.The exact molecular mechanisms underlying AD are still not fully understood,and there are no efficient drugs to stop or reverse the disease progression.In this review,we first provide an update on how the risk factors,including APOE variants,infections and inflammation,contribute to AD;how Aβand tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration.Then we summarize the commonly used experimental models,diagnostic and prediction strategies,and advances in periphery biomarkers from high-risk populations for AD.Finally,we introduce current status of development of disease-modifying drugs,including the newly officially approved Aβvaccines,as well as novel and promising strategies to target the abnormal pTau.Together,this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies.

关 键 词：Alzheimer’s disease NEURODEGENERATION Tau Β-AMYLOID DIAGNOSIS Drug development 

分 类 号：R74[医药卫生—神经病学与精神病学]